ArticleScientific reports2026
Knockdown of RNA editing proteins reshapes the HepaRG transcriptome and pharmacogene expression.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ADAR-mediated RNA editing in CNS disorders: from pathogenic mechanisms to therapeutic opportunities.Cellular & molecular biology letters · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The RNA-editing proteins ADAR and ADARB1 regulate gene expression through both editing-dependent and editing-independent mechanisms. RNA-Seq analysis of HepaRG cells after knocking down (KD) either protein caused widespread transcriptomic changes, including nearly 1,000 pharmacogenes that were either differentially expressed or alternatively spliced, with isoform switches observed in HNF4A and CYP2C9. These effects were editing-independent, and the two treatments primarily affected distinct gene sets, with ADAR KD having broader effects than ADARB1 KD. Because ADAR KD triggers a type I interferon response, we compared siADAR and IFNα treatments. Although both activated interferon signaling, their transcriptional profiles differed markedly. Despite this, 70% of siADAR-responsive genes were rescued by BX795, an inhibitor of the interferon pathway. Therefore, many of siADAR’s effects are likely due to the activation of immune pathways. Overall, our findings indicated that the ADARs maintain hepatic homeostasis and regulate numerous pharmacogenes, especially those involved in drug metabolism and disposition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.